seekingalpha.com · 17 jun

Edgewise Therapeutics, Inc. (EWTX) Discusses Top Line Data From EDG-7500 Phase II CIRRUS-HCM Trial in Hypertrophic Cardiomyopathy Transcript

Edgewise Therapeutics, Inc. (EWTX) Discusses Top Line Data From EDG-7500 Phase II CIRRUS-HCM Trial in Hypertrophic Cardiomyopathy Transcript

benzinga.com · 16 jun

Edgewise Therapeutics Reports Improvements In Heart Drug Trial

Edgewise Therapeutics Inc. (NASDAQ:EWTX) on Tuesday released topline results from the 12-week Part D cohort of its Phase 2 CIRRUS-HCM trial.

reuters.com · 16 jun

Edgewise shares slip after heart-disease drug trial data disappoints investors

Edgewise Therapeutics shares fell nearly 10% on Tuesday after the efficacy of its experimental heart-disease drug in a mid-stage study ​fell short of investor expectations.

prnewswire.com · 16 jun

Edgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with EDG-7500 in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy (HCM)

– No relationship observed between EDG-7500 exposure and LVEF; no LVEF reductions below 50% – – Consistent and clinically meaningful improvements observed in echocardiogram parameters, biomarkers, symptoms and functional status across obstructive and nonobstructive HCM  – – EDG-7500 administration continued to be generally well tolerated – – Company to host webcast today at 8:30 a.m. Eastern Time – BOULDER, Colo.

seekingalpha.com · 4 jun

Edgewise: 'Buy' On Muscular Dystrophy Program Sale And EDG-7500 Advancement

Edgewise Therapeutics remains a "Buy," driven by pipeline focus and a transformative $2.65B sale of its muscular dystrophy program to Servier. Company will use the $1.55B upfront cash to fully fund EDG-7500 development for oHCM/nHCM, targeting pivotal phase 3 initiation in Q4 2026. Topline 12-week Part D data from the phase 2 CIRRUS-HCM study for EDG-7500 is expected in Q2 2026, a key catalyst for advancing to phase 3.

prnewswire.com · 3 jun

Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

BOULDER, Colo., June 3, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions, today announced that on May 29, 2026, Edgewise granted inducement stock options to purchase a total of 74,000 shares of Edgewise's common stock to 4 new non-executive employees in connection with the commencement of their employment, pursuant to Edgewise's 2024 Inducement Equity Incentive Plan (the "Inducement Plan").

zacks.com · 2 jun

Edgewise Therapeutics Stock Hits Record High on $2.65B Servier Deal

EWTX surges 18% to a record high after striking a $2.65 billion neuromuscular business divestiture deal with Servier, sharpening focus on its cardiovascular pipeline.

reuters.com · 1 jun

Edgewise to sell muscle dystrophy business to Servier for up to $2.65 billion

Biotech firm Edgewise Therapeutics said on Monday it would sell its experimental muscular dystrophy drug and related business to ​France's Servier for up to $2.65 billion.